Assessment of the CALLY Index, a Novel Immunonutrivite Marker, in Perioperatively Treated Gastric Cancer Patients
Prognostic Value of the CALLY Index in Gastric Cancer
Keywords:
gastric cancer, albumin, CRP, prognostic valueAbstract
Aim: This study aimed to investigate the prognostic significance of the CALLY index in early-stage gastric cancer patients and compare with other immune markers such as SII, NLR, and PNI.
Methods: We retrospectively analyzed early stage gastric cancer patients treated with adjuvant or perioperative chemotherapy. Laboratory results were obtained from preoperative period. CALLY index was calculated as: Serum albumin level (g/dL) x absolute lymphocyte counts (109/L) / CRP (mg/dL) x104.
Results: A total of 74 patients were included in the study. The median RFS was 13.0 (95 %CI: 7.7-18.2) months in the low-CALLY-index group and 38.2 (95%CI:18.4-57.8) months in the high-CALLY-index group (p<0.001). The median OS was 25.0 (95%CI: 17.1-32.8) months in the low-CALLY-index group and 60.4 (95%CI:45.8-74.1) months in high-CALLY-index group (p<0.001). In multivariate cox regression analyses, low-CALLY-index was independent risk factors for both RFS and OS.
Conclusion: The CALLY index was a prognostic factor for both RFS and OS, with a higher prognostic value compared to other prognostic factors (NLR, PNI, SII).